argenx has made several notable developments and breakthroughs predominantly in steroid-sparing therapeutics and autoimmune disease treatments. The biotech entity has significantly advanced the clinical development of Efgartigimod SC inIdiopathic Inflammatory Myopathies, and their collaboration with
Steritas furthers such development. Their
Efgartigimod drug has successfully hit its primary endpoint in Phase 2 of the Myositis trial.
argenx’s Vyvgart is progressively gaining traction in the CIDP market, showing potential for ten indications by 2030. The launch received a significant boost following
Zai Lab’s and argenx's announcement of VYVGART Hytrulo's approval for CIDP in China. This move is expected to aid argenx in maintaining its dominance in the autoimmune category.
argenx SE, according to Barclays, is on a bullish streak following positive trial results. Based on the company’s fantastic 317% return over the last five years, investors are expected to be pleased. Financial results for Q3 2024 reveal strong sales growth amidst strategic challenges. argenx and Zai Lab also secured a China approval for Vyvgart Hytrulo, which might additionally boost sales.
argenx News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Fri, 22 Nov 2024 14:06:03 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -2
